Publication date: Available online 26 July 2017
Source:Clinical Biochemistry
Author(s): Tobias Breidthardt, Zaid Sabti, Ronny Ziller, Frank Rassouli, Raphael Twerenbold, Nikola Kozhuharov, Etienne Gayat, Samyut Shrestha, Sara Barata, Patrick Badertscher, Jasper Boeddinghaus, Thomas Nestelberger, Christian Mueller
BackgroundThe accurate early diagnosis of acute kidney injury (AKI) in patients with acute heart failure (AHF) is an unmet clinical need. Cystatin C might improve the early detection of AKI.Methods207 patients presenting to the emergency department with AHF were enrolled. Cystatin C was measured in plasma in a blinded fashion at presentation and serially thereafter. The potential of Cystatin C levels to predict AKI was assessed as the primary endpoint. Long-term mortality was assessed as a secondary endpoint.ResultsAt presentation, creatinine (140μmol/L [91–203] vs. 97μmol/L [76–132], p<0.01) and Cystatin C (2.00mg/L [1.30–3.08] vs. 1.45mg/L [1.00–1.90], p<0.01) levels were significantly higher in AKI compared to Non-AKI patients. The diagnostic accuracy for AKI quantified by the area under the receiver operating characteristic curve was mediocre and comparable for both markers (creatinine 0.68; 95%CI 0.58–78 vs. Cystatin C 0.67; 95%CI 0.58–0.76). Serial measurements of Cystatin C did not further increase the prognostic accuracy for AKI. Cystatin C levels were significantly higher in decedents than in survivors (1.90mg/L [1.30–2.70] vs. 1.30mg/L [1.0–1.6], p<0.001). The combination of Cystatin C and BNP levels significantly improved the prediction of mortality provided by either parameter alone. In multivariable regression analysis Cystatin C remained independently associated with mortality (HR 1.41; 95%CI 1.02–1.95).ConclusionPlasma Cystatin C levels do not adequately predict AKI in patients with AHF. However, in multivariable regression analysis Cystatin C predicted mortality after the adjustment for baseline renal function, AKI, BNP levels and heart failure risk factors.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2eOatQl
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
New analysis shows that some of these amazing flying beasts were far more formidable than we'd ever thought before... -- Read more on...
-
Do you speak NHS?Oh, yes: you don’t get far in the health service without being able to generate a seamless flow of the right words, if only...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oDLxf6 via IFTTT
-
The government has announced its intention to make sex and relationships education (SRE) statutory in all secondary schools, and to make rel...
-
Abstract Purpose The aim of this study is to evaluate the feasibility of a telehealthcare application for operable lung cancer (OLC) patie...
-
Bristol-Myers Squibb Co Cancer Drug Cost Comes Under Fire In U.K. StockNews.com (blog) NICE noted the evidence that nivolumab can ext...
-
Abstract Background Medical therapy efficacy remains controversial in stricturing Crohn's disease. Cross-sectional imaging, especial...
-
Abstract The applicability of comprehensive two-dimensional gas chromatography (GC×GC) using a single-stage thermal modulator was explored...
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2o3hqws via IFTTT
-
Abstract Patients with sulfite oxidase (SO) deficiency present severe brain abnormalities, whose pathophysiology is not yet elucidated. We...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου